Skip to Navigation
London School of Hygiene & Tropical Medicine Malaria Centre

Malaria research in drug development, deployment and resistance

The ACT Consortium: a research consortium to optimize the delivery of effective anti-malarial treatment.

LSHTM investigators:
Evelyn Ansah, Daniel Chandramohan, Sian Clarke, Catherine Goodman, Harparkash Kaur, Toby Leslie, Seth Owusu-Agyei, Hugh Reyburn, Mark Rowland, Sarah Staedke, Jayne Webster, Virginia Wiseman, Clare Chandler, Bonnie Cundill, Kristian Hansen, Shunmay Yeung, Christopher Whitty & David Schellenberg.
External collaborators:
Salim Abdullah (Ifakara Health Research & Development Centre, Tanzania); Karen Barnes (University of Cape Town, South Africa); Anders Bjorkman (Karolinska Institutet, Sweden); Emma Davies, David Lalloo, Munir Pirmohamed & Steven Ward (Liverpool School of Tropical Medicine, UK); Facundo Fernandez (Georgia Institute of Technology, USA); Michael Green & Patrick Kachur (Centers for Disease Control & Prevention, USA); Martha Lemnge (National Institute for Medical Research, Tanzania); Pascal Magnussen & Lasse Vestergaard (University of Copenhagen, Denmark); Wilfred Mbacham (University of Yaounde, Cameroon); Anthony Mbonye & Richard Ndyomugyenyi (Ministry of Health, Uganda); Paul Newton (University of Oxford, UK), Obinna Onwujekwe (University of Nigeria, Nigeria), & Kamija Phiri (University of Malawi, Malawi).
Funding body:
The Bill & Melinda Gates Foundation.

The ACT Consortium is an international research collaboration aiming to maximize the public health impact of artemisinin-based combination therapy (ACT) through high quality, policy-driven, multidisciplinary operational  research.

Active in 10 countries and with partners world-wide, we use a variety of study designs including complex evaluations to address questions about:

  • How to improve access to good-quality ACTs for those who most need them;
  • How to target ACTs to patients with malaria, through the deployment of Rapid Diagnostic Tests;
  • Drug quality, by assessing the prevalence of sub-standard and counterfeit artemisinin drugs;
  • The safety of ACTs under operational conditions, especially in high risk groups and when used in combination with other drugs.

Answering these key questions will help give policy makers and programme managers the evidence they need to ensure effective alaria control programmes can be implemented.